MESOTIP: Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy vs. systemic chemotherapy alone as 1st-line treatment of malignant peritoneal mesothelioma.
Pleura Peritoneum
; 4(2): 20190010, 2019 Jun 01.
Article
in En
| MEDLINE
| ID: mdl-31417958
ABSTRACT
BACKGROUND:
Malignant peritoneal mesothelioma (MPM) is a rare tumoral disease characterized by the diffuse involvement of the peritoneal serosa. The standard frontline treatment of MPM is cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) unless the peritoneal disease is considered unresectable. For unresectable patients the standard frontline treatment is a combination of cisplatin and pemetrexed but the prognosis remains ominous with only 13 months of overall survival (OS).METHODS:
The proposed study is a multicenter randomized non-comparative study evaluating the association of Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) and systemic chemotherapy vs. systemic chemotherapy alone as first-line treatment of MPM. Patients will be randomized with a 21 ratio using a minimization technique. Sixty-six patients have to be enrolled. Stratification will be performed according to histology (epithelioid vs. sarcomatoid and biphasic), presence of extraperitoneal disease and center. Primary objective is OS and secondary objectives include progression-free survival (PFS), safety, compliance, feasibility, conversion to resectability, histological response to treatment and quality of life.CONCLUSIONS:
We expect to show that intensification of the first line treatment with PIPAC for initially unresectable MPM patients increases OS. TRIAL REGISTRATION Prospective study. Clinicaltrials.gov NCT03574493 EudraCT 2019-001515-23.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Clinical_trials
/
Observational_studies
/
Risk_factors_studies
Aspects:
Patient_preference
Language:
En
Journal:
Pleura Peritoneum
Year:
2019
Document type:
Article
Affiliation country:
France